RedHill Biopharma Deal History & Licensing Activity
RedHill Biopharma is a biotech headquartered in Israel. Over the past three years, RedHill Biopharma has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Other
Focus Area
Infectious Disease
RedHill Biopharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving RedHill Biopharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Rebyota (global) and Clenpiq (US) | Ferring Pharmaceuticals | Other | Approved | license | Sep 1, 2026 |
RedHill Biopharma Pipeline Focus
Therapeutic areas and modalities where RedHill Biopharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches RedHill Biopharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About RedHill Biopharma Licensing & Deal Activity
RedHill Biopharma is a biotech company based in Israel that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, RedHill Biopharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for RedHill Biopharma include Infectious Disease (3 deals and trials), and Gastroenterology (1 deal and trial). In terms of modality, RedHill Biopharma has shown particular interest in other, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for RedHill Biopharma and 700+ other biopharma companies. Use our Solidus to benchmark your asset against RedHill Biopharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.